Skip to main content

Advertisement

SpringerLink
Log in

The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Our objective is to explore the effects of levetiracetam on the levels of neuropeptides, serum activity and concentrations of oxidative stress and inflammatory response proteins, and levels of brain injury marker in patients with refractory epilepsy. Seventy-two patients with refractory epilepsy received levetiracetam treatment. Neuropeptides galanin (GAL) and neuropeptide Y (NPY) in plasma and cerebrospinal fluid (CSF) were detected using double-antibody sandwich immunoassay and radioimmunoassay, respectively. Enzyme-linked immunosorbent assay was used to detect serum activity of paraoxonase (PON1) and serum concentrations of oxidized low-density lipoprotein (ox-LDL) and S100B. Arylesterase (ARE) activity was measured by colorimetric assay, and immune scatter turbidimetry was used to detect a high-sensitivity C-reactive protein (hs-CRP). After treatment, NPY and GAL in plasma and CSF of the patients were significantly decreased as compared to concentrations before treatment (P < 0.05). Levetiracetam reduced serum activities of PON1 and ARE (P < 0.05) and led to markedly increased serum levels of ox-LDL (P < 0.05). Serum concentrations of hs-CRP and S100B protein were significantly lower after levetiracetam administrations than before treatment (P < 0.05). Levetiracetam treatment had a clear beneficial effect on the overall quality of life (QOL) scores of the patients, as indicated by significantly improved cognitive functioning, behavior problems, emotional conditioning, physical condition, social functioning, self-assessed life quality score, self-assessed health score, and the total QOL score (P < 0.05). Levetiracetam can improve life quality of patients with refractory epilepsy, decrease NPY and GAL in plasma and cerebrospinal fluid, serum PON1 and ARE activities, and serum levels of ox-LDL, hs-CRP, and S100B. Levetiracetam therefore may be considered a drug of choice for treating refractory epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sobayo, T., Fine, A. S., Gunnar, E., et al. (2013). Synchrony dynamics across brain structures in limbic epilepsy vary between initiation and termination phases of seizures. IEEE Transactions on Biomedical Engineering, 60(3), 821–829.

    Article  PubMed  Google Scholar 

  2. Quintas, R., Alvarez, A. S., Koutsogeorgou, E., et al. (2012). The relationship between health-related quality-of life and disability in patients with controlled epilepsy: A cross-sectional observational study. American Journal of Physical Medicine and Rehabilitation, 91(2Suppl), S31–S38.

    Article  PubMed  Google Scholar 

  3. Muzik, O., Pai, D., Juhasz, C., et al. (2013). The need for clinical quantification of combined PET/MRI data in pediatric epilepsy. Nuclear Instruments & Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment, 702, 42–46.

    Article  CAS  Google Scholar 

  4. Semah, F., & Ryvlin, P. (2005). Can we predict refractory epilepsy at the time of diagnosis? Epileptic Disorders, 7(Suppl. 1), S10–S13.

    PubMed  Google Scholar 

  5. Riney, C. J., Chong, W. K., Clark, C. A., et al. (2012). Voxel based morphometry of FLAIR MRI in children with intractable focal epilepsy: Implications for surgical intervention. European Journal of Radiology, 81(6), 1299–1305.

    Article  PubMed  Google Scholar 

  6. Wirrell, E., Wong-Kisiel, L., Mandrekar, J., et al. (2012). Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: A retrospective, population-based study. Epilepsia, 53(9), 1563–1569.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Berger, I., Dor, T., Halvardson, J., et al. (2012). Intractable epilepsy of infancy due to homozygous mutation in the EFHC1 gene. Epilepsia, 53(8), 1436–1440.

    Article  CAS  PubMed  Google Scholar 

  8. Baraban, S. C., & Tallent, M. K. (2004). Interneuron Diversity series: Interneuronal neuropeptides–endogenous regulators of neuronal excitability. Trends in Neuroscience, 27, 135–142.

    Article  CAS  Google Scholar 

  9. Kovac, S., & Walker, M. C. (2013). Neuropeptides in epilepsy. Neuropeptides, 47(6), 467–475.

    Article  CAS  PubMed  Google Scholar 

  10. Mazarati, A. M., Liu, H., Soomets, U., et al. (1998). Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. Journal of Neuroscience, 18, 10070–10077.

    CAS  PubMed  Google Scholar 

  11. Oliver, C. N., Starke-Reed, P. E., Stadtman, E. R., et al. (1990). Oxidative damage to brain proteins, loss of glutamine synthetase activity and production of free radicals during ischemia/reperfusion induced injury to gerbil brain. Proceedings of the National Academy of Sciences USA, 87, 5144–5147.

    Article  CAS  Google Scholar 

  12. Finkel, T., & Holbrook, N. J. (2000). Oxidants, oxidative stress and the biology of ageing. Nature, 408(9), 239–247.

    Article  CAS  PubMed  Google Scholar 

  13. Jeding, I., Evans, P. J., Akanmu, D., et al. (1995). Characterization of the potential antioxidant and prooxidant actions of some neuroleptic drugs. Biochemical Pharmacology, 49, 359–365.

    Article  CAS  PubMed  Google Scholar 

  14. Tan, T. Y., Lu, C. H., Chuang, H. Y., et al. (2009). Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia, 50, 1579–1586.

    Article  CAS  PubMed  Google Scholar 

  15. Belcastro, V., D’Egidio, C., Striano, P., et al. (2013). Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Research, 107, 1–8.

    Article  CAS  PubMed  Google Scholar 

  16. Shahabadi, N., & Hadidi, S. (2012). Spectroscopic studies on the interaction of calf thymus DNA with the drug levetiracetam. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 96A, 278–283.

    Article  Google Scholar 

  17. Can, Nafiz O., & Arli, Goksel. (2010). Reversed-phase HPLC analysis of levetiracetam in tablets using monolithic and conventional C18 silica columns. Journal of AOAC International, 93(4), 1077–1085.

    CAS  PubMed  Google Scholar 

  18. Alonso-Lomillo, M. A., Dominguez-Renedo, O., Matos, P., et al. (2009). Electrochemical determination of levetiracetam by screen-printed based biosensors. Bioelectrochemistry, 74(2), 306–309.

    Article  CAS  PubMed  Google Scholar 

  19. Mangelings, D., Saevels, J., Vander Heyden, Y., et al. (2006). Enantiomeric impurity determination of levetiracetam using capillary electrochromatography. Journal of Separation Science, 29(18), 2827–2836.

    Article  CAS  PubMed  Google Scholar 

  20. Liao, F., Liu, W. L., Zhou, Q. X., et al. (2001). Assay of serum arylesterase activity by fitting to the reaction curve with an integrated rate equation. Clinica Chimica Acta, 314(1–2), 67–76.

    Article  CAS  Google Scholar 

  21. Kim, Y. M., Vaidya, V. V., Khusainov, T., et al. (2012). Various indications for a modified Atkins diet in intractable childhood epilepsy. Brain & Development, 34(7), 570–575.

    Article  Google Scholar 

  22. Ghareeb, F., & Duffau, H. (2012). Intractable epilepsy in paralimbic Word Health Organization Grade II gliomas: Should the hippocampus be resected when not invaded by the tumor? Clinical article. Journal of Neurosurgery, 116(6), 1226–1234.

    Article  PubMed  Google Scholar 

  23. Endoh, F., Kobayashi, K., Hayashi, Y., et al. (2012). Efficacy of topiramate for intractable childhood generalized epilepsy with epileptic spasms: With special reference to electroencephalographic changes. Seizure, 21(7), 522–528.

    Article  PubMed  Google Scholar 

  24. Guimarães, J., & Ribeiro, J. A. (2010). Pharmacology of antiepileptic drugs in clinical practice. Neurologist, 16(6), 353–357.

    Article  PubMed  Google Scholar 

  25. Larkin, T. M., Cohen-Oram, A. N., Catalano, G., et al. (2013). Overdose with levetiracetam: A case report and review of the literature. Journal of Clinical Pharmacy and Therapeutics, 38(1), 68–70.

    Article  CAS  PubMed  Google Scholar 

  26. Fertig, J. B., Ryan, M. L., Falk, D. E., et al. (2012). A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcoholism, 36(8), 1421–1430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chen, K.-F., Lai, S.-C., Wu, Y.-C., et al. (2013). Functional neuroimages of cortical myoclonus altered by levetiracetam in a patient with sialidosis. Journal of Clinical Neuroscience, 20(2), 324–325.

    Article  PubMed  Google Scholar 

  28. Schiemann-Delgado, J., Yang, H., DeLaLoge, C., et al. (2012). A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. Journal of Child Neurology, 27(1), 80–89.

    Article  PubMed  Google Scholar 

  29. Soni, S., Skeens, M., Termuhlen, A. M., et al. (2012). Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatric Blood & Cancer, 59(4), 762–764.

    Article  Google Scholar 

  30. Freitas, R. M. (2009). Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neuroscience Letters, 462(3), 225.

    Article  CAS  PubMed  Google Scholar 

  31. Verrotti, A., Sardapane, A., Franzoni, E., et al. (2008). Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Research, 78(2–3), 171.

    Article  CAS  PubMed  Google Scholar 

  32. Schulpis, K. H., Lazaropoulou, C., Regoutas, S., et al. (2006). Valproic acid monotherapy induces DNA oxidative damage. Toxicology, 217(2–3), 228.

    Article  CAS  PubMed  Google Scholar 

  33. Karikas, G. A., Schulpis, K. H., Bartzeliotou, A., et al. (2009). Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities. Scandinavian Journal of Clinical and Laboratory Investigation, 69(1), 31.

    Article  CAS  PubMed  Google Scholar 

  34. Varoglu, A. O., Yildirim, A., Aygul, R., et al. (2010). Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clinical Neuropharmacology, 33, 155–157.

    Article  CAS  PubMed  Google Scholar 

  35. Yildiz, M., Simsek, G., Uzun, H., et al. (2010). Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs. Cardiology Young, 20, 547–554.

    Article  Google Scholar 

  36. Yildiz, A., Sezen, Y., Gur, M., et al. (2008). Association of paraoxonase activity and coronary collateral flow. Coronary Artery Disease, 19, 441–447.

    Article  PubMed  Google Scholar 

  37. Cavadas, C., Cefai, D., Rosmaninho-Salgado, J., et al. (2006). Deletion of the neuropeptide Y (NPY) Y-1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion. Proceedings of the National Academy of Sciences of the United States of America, 103(27), 10497–10502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Funkelstein, L., Lu, W. D., Koch, B., et al. (2012). Human cathepsin V protease participates in production of enkephalin and NPY neuropeptide neurotransmitters. The Journal of biological chemistry, 287(19), 15232–15241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Tu, B., Jiao, Y., Herzog, H., et al. (2006). Neuropeptide Y regulates recurrent mossy fiber synaptic transmission less effectively in mice than in rats: Correlation with Y2 receptor plasticity. Neuroscience, 143(4), 1085–1094.

    Article  CAS  PubMed  Google Scholar 

  40. Takeuchi, T., Nishiyama, K., Yamada, A., et al. (2011). Caenorhabditis elegans proteins captured by immobilized Galβ1-4Fuc disaccharide units: Assignment of 3 annexins. Carbohydrate Research, 346(13), 1837–1841.

    Article  CAS  PubMed  Google Scholar 

  41. Vezzani, A., & Granata, T. (2005). Brain inflammation in epilepsy: Experimental and clinical evidence. Epilepsia, 6(11), 1740–1743.

    Google Scholar 

  42. Sutula, T. P., Hagen, J., & Pitkanen, A. (2003). Do epileptic seizures damage the brain. Current Opinion in Neurology, 16(2), 189–195.

    Article  PubMed  Google Scholar 

  43. Kleindienst, A., Hesse, F., Bullock, M. R., et al. (2007). The neurotrophic protein S100B: Value as a marker of brain damage and possible therapeutic implications. Progress Brain Research, 161, 317–325.

    Article  CAS  Google Scholar 

  44. Kaciński, M., Budziszewska, B., Lasoń, W., et al. (2012). Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacological Reports, 64(6), 1427–1433.

    Article  PubMed  Google Scholar 

  45. Portela, L. V., Tort, A. B., Walz, R., et al. (2003). Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy. Acta Neurologica Scandinavica, 108(6), 424–427.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Neurology, (Shanghai Tenth People’s Hospital), Tenth People’s Hospital of Tongji University, No. 301 Middle Yanchang Road, Shanghai, 200072, China

      Wenzhen Chen, Yan Tan, Yuxing Ge, Yujuan Chen & Xueyuan Liu

    Authors
    1. Wenzhen Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Yan Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yuxing Ge
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yujuan Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Xueyuan Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Yujuan Chen or Xueyuan Liu.

    Additional information

    Wenzhen Chen and Yan Tan have contributed equally to this study.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Chen, W., Tan, Y., Ge, Y. et al. The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy. Cell Biochem Biophys 73, 489–494 (2015). https://doi.org/10.1007/s12013-015-0683-8

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12013-015-0683-8

    Keywords

    Search

    Navigation